Neuroendocrine Tumour of the Lung Completed Phase 2 Trials for Durvalumab (DB11714)

Also known as: Pulmonary Neuroendocrine Tumor / Neuroendocrine Neoplasm of Lung / Neuroendocrine Tumor of the Lung / Pulmonary Neuroendocrine Tumors / Neuroendocrine Tumors in Lung / Neuroendocrine neoplasm of lung (disorder)

IndicationStatusPhase
DBCOND0133412 (Neuroendocrine Tumour of the Lung)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03095274Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung OriginTreatment